Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company

Legend Biotech Corporation Appoints Alan Bash as President of Carvykti

Fineline Cube Nov 5, 2024

China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...

Company Deals

Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology

Fineline Cube Nov 5, 2024

Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...

Company Deals

Mirxes Holding Company Updates IPO Prospectus with 2024 Financials

Fineline Cube Nov 5, 2024

Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...

Company Deals

Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline

Fineline Cube Nov 5, 2024

China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...

Company Medical Device

Shanghai HeartCare Medical Technology Receives NMPA Approval for Embolization Stent

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology...

Company Deals

Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments

Fineline Cube Nov 5, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center...

Company Drug

HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment

Fineline Cube Nov 5, 2024

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...

Company Medical Device

NMPA Grants Marketing License to Abonisi Medical Technology’s Knee Joint Prosthesis System

Fineline Cube Nov 5, 2024

China’s National Medical Products Administration (NMPA) has issued a marketing license to Abonisi Medical Technology...

Company Drug

Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging

Fineline Cube Nov 5, 2024

Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...

Company Drug

China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment

Fineline Cube Nov 5, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...

Company Digital

111 Inc. Appoints Yang “Luke” Chen to Board of Directors Following Resignation of Dr. Lian Yong Chen

Fineline Cube Nov 5, 2024

China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance...

Company Deals

Shanghai RMX Biopharma and PharmaEngine Ink Distribution Deal for Liporaxel in Taiwan

Fineline Cube Nov 4, 2024

Chinese firms Shanghai RMX Biopharma Co. Ltd., a subsidiary of Haihe Biopharma Co., Ltd., and...

Policy / Regulatory

China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing

Fineline Cube Nov 4, 2024

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

Fineline Cube Nov 4, 2024

The National Medical Products Administration (NMPA) has released the 84th batch of reference drugs for...

Company Medical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Fineline Cube Nov 4, 2024

US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...

Company Drug

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015

Fineline Cube Nov 4, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...

Company Drug

Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial

Fineline Cube Nov 4, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...

Company Deals

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing

Fineline Cube Nov 4, 2024

Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful...

Company Medical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Fineline Cube Nov 4, 2024

China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...

Company Deals

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Fineline Cube Nov 4, 2024

Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...

Posts pagination

1 … 300 301 302 … 693

Recent updates

  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.